TCM
DNA icon

Trybe Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Trybe Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-94,519
Closed -$7.03M – 15
2023
Q2 		$7.03M Buy
94,519
+68,160
+259% +$4.03M 4.08% 15
2023
Q1 		$1.4M Buy
+26,359
New +$1.67M 1.25% 12
2022
Q4 		– Sell
-26,359
Closed -$3.29M – 11
2022
Q3 		$3.29M Hold
26,359
– – 3.29% 12
2022
Q2 		$2.51M Sell
26,359
-3,841
-13% -$468K 2.18% 11
2022
Q1 		$4.87M Hold
30,200
– – 2.95% 11
2021
Q4 		$10M Hold
30,200
– – 5.3% 11
2021
Q3 		$14M Buy
+30,200
New +$14.7M 7.97% 7

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return